← Back

Wire · operational-macro

FDA Approves Adrabetadex as First Therapy Shown to Improve Survival in Infantile-Onset ...

Published

17 November 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at neurologylive.com →

◆ Verified

Fusion42 · 17 November 2026 · Fusion42 review

The FDA approved adrabetadex (Lembaz) as the first therapy shown to extend survival in infantile-onset Niemann-Pick disease type C (I-NPC) patients weighing at least 7 kg, reducing mortality risk by 55%. The intrathecal treatment addresses CNS cholesterol accumulation but carries risks including irreversible hearing loss requiring close audiometric monitoring.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it.

◆ ◆ The Wire takeaway

You can enter the rare pediatric neurodegenerative space now that adrabetadex has set a survival benchmark with FDA approval. Test clinics and advocacy groups will be open doors for early users, but manage hearing risks tightly to keep patients on treatment.

◆ Coverage

3 sources · 17 Nov 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvalrare-diseaseinfantile-onsetadrabetadexnpcsurvival-benefit